ACIU

#3405
AC Immune SA - Common Stock
2.6 7 USD
+0.01%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
2.67
2.69
Intervallo Annuale
2.04
4.00
Variazione giornaliera
+0.75%
Variazione Mensile
+19.20%
Variazione di 6 mesi
-5.65%
Variazione Annuale
+28.37%
Chiusura Precedente
2.6 5
Open
2.6 9
Minimo
2.6 7
Massimo
2.6 9
Volume
8
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
AC Immune SA current report, Q3 FY2026
6-K
Current report, Q3 FY2026
AC Immune SA current report, Q3 FY2026
6-K
Current report, Q2 FY2026
AC Immune SA current report, Q2 FY2026
6-K
Current report, Q2 FY2026
AC Immune SA current report, Q2 FY2026
6-K
Current report, Q2 FY2026
AC Immune SA current report, Q2 FY2026
6-K
Current report, Q2 FY2026
AC Immune SA current report, Q2 FY2026
6-K
Current report, Q2 FY2026
AC Immune SA current report, Q2 FY2026
6-K
Current report, Q2 FY2026
AC Immune SA current report, Q2 FY2026
6-K
Current report, Q2 FY2026
AC Immune SA current report, Q2 FY2026
6-K
Current report, Q2 FY2026
AC Immune SA current report, Q2 FY2026
6-K

AC Immune SA current report, Q2 FY2026

Full document

Business Context and Reporting Period

This Form 6-K filing by AC Immune SA reports on the Annual General Meeting (AGM) of Shareholders held on June 11, 2026. The filing details the approval of the 2025 financial statements, compensation reports, and various corporate governance resolutions.

Key Financial Metrics

  • Net Loss (2025): CHF 67,595K.
  • Accumulated Losses: Increased from CHF 356,846K to CHF 424,441K following the appropriation of 2025 losses.
  • Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide specific values for these metrics; it only references the approval of the 2025 IFRS Consolidated Financial Statements.

Material Changes and Corporate Actions

  • Capital Structure: Shareholders approved a new capital band with an upper limit of CHF 2,862,500.00 and a lower limit of CHF 2,202,018.50, valid until June 11, 2031.
  • Employee Benefit Plans: Conditional share capital for employee benefit plans was increased from CHF 86,683.80 to CHF 150,000.00.
  • Compensation Caps:
    • Board of Directors (AGM 2026 to AGM 2027): CHF 1,029K.
    • Executive Management (Financial Year 2027): CHF 6,742K.

Guidance, Outlook, and Governance

  • Management Commentary: The filing incorporates by reference the Management presentation to shareholders (Exhibit 99.1) but does not contain specific text regarding future guidance or operational outlook within this document.
  • Board Re-elections: Shareholders re-elected René Aguiar-Lucander, Monika Büttler, Carl June, Roy Twyman, and Martin Zügel (Chair) to the Board of Directors until the 2027 AGM.
  • Auditors and Proxy: PricewaterhouseCoopers SA was re-elected as Statutory Auditor for 2026, and Reymond & Associés Attorneys was re-elected as Independent Proxy until the 2027 AGM.
  • Risks and Contingencies: No specific risks or contingencies are detailed in this filing text.

Investor Verification Checklist

  • Verify the full 2025 IFRS Consolidated Financial Statements for detailed revenue, cash flow, and liquidity data not present in this summary.
  • Review the Management presentation (Exhibit 99.1) for strategic outlook and operational updates.
  • Confirm the specific terms of the newly authorized capital band and its potential impact on share dilution.
  • Check the company website for the detailed AGM minutes as promised within 15 days of the meeting.

Notizie